Bristol-Myers Squibb (BMY) Tops Q1 EPS by 28c ; Offers Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.80, $0.28 better than the analyst estimate of $1.52. Revenue for the quarter came in at $11.2 billion versus the consensus estimate of $10.68 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2025 EPS of $6.70-$7.00, versus the consensus of $6.74. Bristol-Myers Squibb sees FY2025 revenue of $45.8-46.8 billion, versus the consensus of $45.76 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
• JPMorgan Upgrades Kolmar Korea Co Ltd (161890:KS) to Overweight